| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| Jessica Amarù, Federica Barbieri, Marica Arvigo, Agnese Solari, Adriana Bajetto, Federica Nista, Claudia Campana, Gabriele Gaggero, Alessandro Prior, Diego Criminelli Rossi, Gianluigi Zona, Diego Ferone, Tullio Florio, Federico Gatt. Octreotide and Pasireotide Combination Treatment in Somatotroph Tumor Cells: Predominant Role of SST Cancers. vol 13. issue 8. 2021-05-02. PMID:33920241. |
octreotide and pasireotide combination treatment in somatotroph tumor cells: predominant role of sst first-generation somatostatin receptor ligands (fg-srls), such as octreotide (oct), represent the first-line medical therapy in acromegaly. |
2021-05-02 |
2023-08-13 |
Not clear |
| David Cella, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S Kha. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Advances in therapy. vol 38. issue 2. 2021-04-14. PMID:33432541. |
patient and healthcare provider perspectives of first-generation somatostatin analogs in the management of neuroendocrine tumors and acromegaly: a systematic literature review. |
2021-04-14 |
2023-08-13 |
Not clear |
| David Cella, Jennifer Evans, Marion Feuilly, Sebastian Neggers, Dirk Van Genechten, Jackie Herman, Mohid S Kha. Patient and Healthcare Provider Perspectives of First-Generation Somatostatin Analogs in the Management of Neuroendocrine Tumors and Acromegaly: A Systematic Literature Review. Advances in therapy. vol 38. issue 2. 2021-04-14. PMID:33432541. |
somatostatin analogs (ssas) are used to treat neuroendocrine tumors (nets) and acromegaly. |
2021-04-14 |
2023-08-13 |
Not clear |
| Zhenmei An, Ting Lei, Lian Duan, Pei Hu, Zhongping Gou, Lihui Zhang, Lucie Durand-Gasselin, Nan Wang, Yan Wang, Feng G. Efficacy and safety of lanreotide autogel compared with lanreotide 40 mg prolonged release in Chinese patients with active acromegaly: results from a phase 3, prospective, randomized, and open-label study (LANTERN). BMC endocrine disorders. vol 20. issue 1. 2021-03-16. PMID:32366244. |
lanreotide autogel is a somatostatin analog (ssa) approved for the treatment of acromegaly in 73 countries worldwide; however, it is not yet approved in china. |
2021-03-16 |
2023-08-13 |
Not clear |
| Eva C Coopmans, Tim I M Korevaar, Sebastiaan W F van Meyel, Adrian F Daly, Philippe Chanson, Thierry Brue, Brigitte Delemer, Václav Hána, Annamaria Colao, Davide Carvalho, Marie-Lise Jaffrain-Rea, Günter K Stalla, Carmen Fajardo-Montañana, Albert Beckers, Aart J van der Lely, Patrick Petrossians, Sebastian J C M M Negger. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 105. issue 9. 2021-02-24. PMID:32589751. |
multivariable prediction model for biochemical response to first-generation somatostatin receptor ligands in acromegaly. |
2021-02-24 |
2023-08-13 |
Not clear |
| Eva C Coopmans, Tim I M Korevaar, Sebastiaan W F van Meyel, Adrian F Daly, Philippe Chanson, Thierry Brue, Brigitte Delemer, Václav Hána, Annamaria Colao, Davide Carvalho, Marie-Lise Jaffrain-Rea, Günter K Stalla, Carmen Fajardo-Montañana, Albert Beckers, Aart J van der Lely, Patrick Petrossians, Sebastian J C M M Negger. Multivariable Prediction Model for Biochemical Response to First-Generation Somatostatin Receptor Ligands in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 105. issue 9. 2021-02-24. PMID:32589751. |
first-generation somatostatin receptor ligands (fg-srls) represent the mainstay of medical therapy for acromegaly, but they provide biochemical control of disease in only a subset of patients. |
2021-02-24 |
2023-08-13 |
Not clear |
| Marco Losa, Enrico Garbin, Erika Pedone, Pietro Mortin. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 105. issue 9. 2021-02-24. PMID:32609842. |
normal insulin-like growth factor 1 during somatostatin receptor ligand treatment predicts surgical cure in acromegaly. |
2021-02-24 |
2023-08-13 |
Not clear |
| Marco Losa, Enrico Garbin, Erika Pedone, Pietro Mortin. Normal Insulin-like Growth Factor 1 During Somatostatin Receptor Ligand Treatment Predicts Surgical Cure in Acromegaly. The Journal of clinical endocrinology and metabolism. vol 105. issue 9. 2021-02-24. PMID:32609842. |
treatment with somatostatin receptor ligands (srls) is often given before pituitary surgery to patients with acromegaly. |
2021-02-24 |
2023-08-13 |
Not clear |
| Vivien Bonert, James Mirocha, John Carmichael, Kevin C J Yuen, Takako Araki, Shlomo Melme. Cost-Effectiveness and Efficacy of a Novel Combination Regimen in Acromegaly: A Prospective, Randomized Trial. The Journal of clinical endocrinology and metabolism. vol 105. issue 9. 2021-02-23. PMID:32754748. |
combination therapy with somatostatin receptor ligand (srl) plus pegvisomant for patients with acromegaly is recommended after a maximizing dose on monotherapy. |
2021-02-23 |
2023-08-13 |
Not clear |
| Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Murray B Gordon, Marek Bolanowski, Artak Labadzhyan, Ehud Ur, Mark Molitch, William H Ludlam, Gary Patou, Asi Haviv, Nienke Biermasz, Andrea Giustina, Peter J Trainer, Christian J Strasburger, Laurence Kennedy, Shlomo Melme. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. The Journal of clinical endocrinology and metabolism. vol 105. issue 10. 2021-02-19. PMID:32882036. |
maintenance of acromegaly control in patients switching from injectable somatostatin receptor ligands to oral octreotide. |
2021-02-19 |
2023-08-13 |
Not clear |
| Susan L Samson, Lisa B Nachtigall, Maria Fleseriu, Murray B Gordon, Marek Bolanowski, Artak Labadzhyan, Ehud Ur, Mark Molitch, William H Ludlam, Gary Patou, Asi Haviv, Nienke Biermasz, Andrea Giustina, Peter J Trainer, Christian J Strasburger, Laurence Kennedy, Shlomo Melme. Maintenance of Acromegaly Control in Patients Switching From Injectable Somatostatin Receptor Ligands to Oral Octreotide. The Journal of clinical endocrinology and metabolism. vol 105. issue 10. 2021-02-19. PMID:32882036. |
the phase 3 chiasma optimal trial (nct03252353) evaluated efficacy and safety of oral octreotide capsules (oocs) in patients with acromegaly who previously demonstrated biochemical control while receiving injectable somatostatin receptor ligands (srls). |
2021-02-19 |
2023-08-13 |
Not clear |
| Anat Ben-Shlomo, Nan Deng, Evelyn Ding, Masaaki Yamamoto, Adam Mamelak, Vera Chesnokova, Artak Labadzhyan, Shlomo Melme. DNA damage and growth hormone hypersecretion in pituitary somatotroph adenomas. The Journal of clinical investigation. vol 130. issue 11. 2021-02-16. PMID:32673291. |
octreotide, a somatostatin receptor ligand that targets somatotroph adenoma gh secretion in patients with acromegaly, inhibited camp and gh and reversed dna damage induction. |
2021-02-16 |
2023-08-13 |
mouse |
| Emmanuelle Kuhn, Philippe Caron, Brigitte Delemer, Isabelle Raingeard, Hervé Lefebvre, Gérald Raverot, Christine Cortet-Rudelli, Rachel Desailloud, Clementine Geffroy, Robin Henocque, Yves Brault, Thierry Brue, Philippe Chanso. Correction to: Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study. Endocrine. vol 71. issue 1. 2021-02-02. PMID:33156493. |
correction to: pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational french acrostudy cohort study. |
2021-02-02 |
2023-08-13 |
Not clear |
| Brandon P Galm, Colleen Buckless, Brooke Swearingen, Martin Torriani, Anne Klibanski, Miriam A Bredella, Nicholas A Trito. MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary. vol 23. issue 3. 2021-02-01. PMID:31897778. |
mri texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. |
2021-02-01 |
2023-08-13 |
Not clear |
| Brandon P Galm, Colleen Buckless, Brooke Swearingen, Martin Torriani, Anne Klibanski, Miriam A Bredella, Nicholas A Trito. MRI texture analysis in acromegaly and its role in predicting response to somatostatin receptor ligands. Pituitary. vol 23. issue 3. 2021-02-01. PMID:31897778. |
given the paucity of reliable predictors of tumor recurrence, progression, or response to somatostatin receptor ligand (srl) therapy in acromegaly, we attempted to determine whether preoperative mr image texture was predictive of these clinical outcomes. |
2021-02-01 |
2023-08-13 |
Not clear |
| Sabrina Chiloiro, Antonella Giampietro, Federica Mirra, Federico Donfrancesco, Tommaso Tartaglione, Pier Paolo Mattogno, Flavia Angelini, Lauretti Liverana, Marco Gessi, Anile Carmelo, Guido Rindi, Andrea Giustina, Maria Fleseriu, Alfredo Pontecorvi, Laura De Marinis, Antonio Bianch. Pegvisomant and Pasireotide LAR as second line therapy in acromegaly: clinical effectiveness and predictors of response. European journal of endocrinology. vol 184. issue 2. 2021-01-22. PMID:33136550. |
the treatment of acromegaly resistant to first-generation somatostatin receptor ligands (srls) is often difficult. |
2021-01-22 |
2023-08-13 |
Not clear |
| Shalini Sree Dharan, Nor Azmi Kamaruddi. Successful Primary Medical Therapy with Somatostatin Receptor Ligand in Acromegaly with Thyroid Cancer. Journal of the ASEAN Federation of Endocrine Societies. vol 32. issue 2. 2021-01-15. PMID:33442102. |
successful primary medical therapy with somatostatin receptor ligand in acromegaly with thyroid cancer. |
2021-01-15 |
2023-08-13 |
Not clear |
| Shinobu Takayasu, Koshi Makita, Kazunori Kageyama, Yuta Okawa, Yutaka Oki, Satoshi Yamagata, Yuko Asari, Ken Terui, Makoto Daimo. Presence of aberrant adrenocorticotropic hormone precursors in two cases of McCune-Albright syndrome. Endocrine journal. vol 67. issue 3. 2021-01-06. PMID:31801917. |
no involvement of 11β-hsd1 by gh excess was suggested because basal levels of acth and cortisol showed no changes, even after therapy for acromegaly by somatostatin analogues. |
2021-01-06 |
2023-08-13 |
Not clear |
| Eliza B Geer, Jill Sisco, Daphne T Adelman, William H Ludlam, Asi Haviv, Dana Gelbaum, Shuqian Liu, Susan D Mathias, Lizheng Sh. Observed discordance between outcomes reported by acromegaly patients and their treating endocrinology medical provider. Pituitary. vol 23. issue 2. 2021-01-04. PMID:31808101. |
acromegaly patients, even those with igf-1 values within the normal range receiving somatostatin receptor ligands (srls), often suffer from significant symptoms. |
2021-01-04 |
2023-08-13 |
Not clear |
| Daphne Adelman, Xuan-Mai Truong Thanh, Marion Feuilly, Aude Houchard, David Cell. Evaluation of Nurse Preferences Between the Lanreotide Autogel New Syringe and the Octreotide Long-Acting Release Syringe: An International Simulated-Use Study (PRESTO). Advances in therapy. vol 37. issue 4. 2020-12-07. PMID:32157626. |
somatostatin analogues are used to treat symptoms and slow tumour progression in patients with neuroendocrine tumours (nets) and carcinoid syndrome and to reduce hormone secretion and pituitary tumour volume in patients with acromegaly. |
2020-12-07 |
2023-08-13 |
human |